2012
Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
De Souza A, Strober B, Merola J, Oliver S, Franks A. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. Journal Of Drugs In Dermatology 2012, 11: 1224-6. PMID: 23134988.Peer-Reviewed Original ResearchConceptsDiscoid lupus erythematosusDiscoid lupusLupus erythematosusCutaneous Lupus Erythematosus Disease AreaFirst open-label studyTh17-mediated immune responsesOpen-label studyChronic inflammatory disordersEffective therapeutic optionDays of treatmentAdverse eventsIL-23Psoriatic arthritisIL-12Clinical efficacyTherapeutic optionsInflammatory disordersTh1 cellsTreatment modalitiesLeukocyte productionImmune responseLabel studyEnzyme inhibitorsApremilastPilot study
2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Strober B, Poulin Y, Kerdel F, Langley R, Gu Y, Gupta S, Okun M, Papp K. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. Journal Of The American Academy Of Dermatology 2011, 64: 671-681. PMID: 21414495, DOI: 10.1016/j.jaad.2010.03.009.Peer-Reviewed Original ResearchConceptsPhysician global assessmentSuboptimal responseSuboptimal therapyWeek 16Global assessmentPhase IIIb trialChronic plaque psoriasisOpen-label designOpen-label studyPrimary end pointPercentage of patientsNB-UVB phototherapySeverity Index scorePsoriasis clinical trialsTreatment of psoriasisDosage taperingIIIb trialPrior therapyPlaque psoriasisPsoriasis AreaPsoriasis flarePsoriasis patientsSafety profilePatient enrollmentClinical trials
2010
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
Leonardi C, Strober B, Gottlieb A, Elewski B, Ortonne J, van de Kerkhof P, Chiou C, Dunn M, Jahreis A. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. Journal Of Drugs In Dermatology 2010, 9: 928-37. PMID: 20684143.Peer-Reviewed Original ResearchConceptsLong-term safetyExtension studyOpen-label etanercept treatmentPrevious phase 3 studyOpen-label extension studyEfficacy of etanerceptOpen-label studySevere plaque psoriasisPhase 3 studySymptoms of psoriasisEligible patientsEtanercept treatmentInterrupted therapySubcutaneous etanerceptEtanercept therapyPlaque psoriasisAdverse eventsPsoriatic patientsEtanerceptPatientsSkin diseasesPsoriasisWeeksYears of experiencePredetermined criteria
2007
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Frankel E, Strober B, Crowley J, Fivenson D, Woolley J, Yu E, Xia H, Chiou C, Stevens S. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007, 79: 322-6. PMID: 17500381.Peer-Reviewed Original Research
2005
Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study
Strober B, Siu K, Alexis A, Kim G, Washenik K, Sinha A, Shupack J. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. Journal Of The American Academy Of Dermatology 2005, 52: 1082-1084. PMID: 15928633, DOI: 10.1016/j.jaad.2005.03.039.Peer-Reviewed Original ResearchConceptsSevere alopecia areataAlopecia areataAlopecia totalisAlopecia universalisOpen-label pilot studyEfficacy of etanerceptOpen-label studyTNF-alpha inhibitorsPrimary outcome measureEnd of treatmentAlopecia ToolHair regrowthOutcome measuresEtanerceptHealthy adultsAreataContinuous treatmentPilot studySignificant regrowthTotalisTreatmentUniversalisSubjectsSeverityWeeks